Maynard Um
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $52 at Guggenheim
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $71 at Goldman Sachs
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $72 at RBC Capital
-
-
-
-
-
-
-
Health Canada approves Evkeeza for infants as young as 6 months with HoFH
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

